Dr. McGregor Compares Recent Data With Combinations in RCC

Bradley McGregor, MD
Published: Tuesday, Jun 05, 2018



Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, compares recent data with combination therapy in renal cell carcinoma (RCC).

Results from the phase III CheckMate-214 trial and the IMmotion151 trial have proven the success of combination therapy in patients with advanced RCC.

In April 2018, the FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a frontline treatment for intermediate- and poor-risk patients with advanced RCC. This approval was based off findings from the phase III CheckMate-214 study, which showed a 32% reduction in the risk of death with the combination compared to sunitinib (Sutent). McGregor says that the most appealing data out of this trial were the complete response (CR) rates, specifically in the PD-L1–positive subgroup, which was 16%. The CR rate for the PD-L1–negative group was comparable with what is seen with interleukin-2, he added.

Findings from the IMmotion151 trial showed that the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) reduced the risk of death by 26% compared with sunitinib in patients with untreated PD-L1–positive metastatic RCC. McGregor says that the most appealing thing about this combination is the toxicity profile. It is a very well-tolerated regimen as opposed to nivolumab plus ipilimumab, where the data suggest the combination is appropriate only for intermediate- and poor-risk patients.
SELECTED
LANGUAGE


Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, compares recent data with combination therapy in renal cell carcinoma (RCC).

Results from the phase III CheckMate-214 trial and the IMmotion151 trial have proven the success of combination therapy in patients with advanced RCC.

In April 2018, the FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a frontline treatment for intermediate- and poor-risk patients with advanced RCC. This approval was based off findings from the phase III CheckMate-214 study, which showed a 32% reduction in the risk of death with the combination compared to sunitinib (Sutent). McGregor says that the most appealing data out of this trial were the complete response (CR) rates, specifically in the PD-L1–positive subgroup, which was 16%. The CR rate for the PD-L1–negative group was comparable with what is seen with interleukin-2, he added.

Findings from the IMmotion151 trial showed that the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) reduced the risk of death by 26% compared with sunitinib in patients with untreated PD-L1–positive metastatic RCC. McGregor says that the most appealing thing about this combination is the toxicity profile. It is a very well-tolerated regimen as opposed to nivolumab plus ipilimumab, where the data suggest the combination is appropriate only for intermediate- and poor-risk patients.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x